Rhumbline Advisers Has $94,000 Stock Position in Zura Bio Limited (NASDAQ:ZURA)

Rhumbline Advisers lifted its position in Zura Bio Limited (NASDAQ:ZURA) by 37.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,657 shares of the company’s stock after buying an additional 10,231 shares during the quarter. Rhumbline Advisers owned about 0.06% of Zura Bio worth $94,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ZURA. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Zura Bio in the third quarter valued at about $46,000. The Manufacturers Life Insurance Company purchased a new stake in Zura Bio in the 3rd quarter valued at $71,000. Valence8 US LP bought a new position in Zura Bio in the 3rd quarter valued at $71,000. SG Americas Securities LLC grew its stake in shares of Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after acquiring an additional 7,828 shares during the period. Finally, MetLife Investment Management LLC bought a new position in Zura Bio in the 3rd quarter worth about $111,000. 61.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZURA shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a report on Wednesday, December 11th. HC Wainwright reissued a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $15.80.

Zura Bio Trading Down 5.6 %

NASDAQ:ZURA opened at $1.19 on Tuesday. The stock has a 50 day moving average of $1.71 and a two-hundred day moving average of $2.97. Zura Bio Limited has a 12 month low of $1.10 and a 12 month high of $6.35.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.